(NASDAQ: VIR) Vir Biotechnology's forecast annual revenue growth rate of 1.44% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 109.19%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 26.12%.
Vir Biotechnology's revenue in 2025 is $16,860,000.On average, 11 Wall Street analysts forecast VIR's revenue for 2025 to be $1,548,600,731, with the lowest VIR revenue forecast at $640,809,897, and the highest VIR revenue forecast at $5,405,007,493. On average, 11 Wall Street analysts forecast VIR's revenue for 2026 to be $1,784,695,910, with the lowest VIR revenue forecast at $409,027,594, and the highest VIR revenue forecast at $4,331,379,621.
In 2027, VIR is forecast to generate $2,542,370,835 in revenue, with the lowest revenue forecast at $409,027,594 and the highest revenue forecast at $5,580,305,034.